Pancreatic Cancer Research

ResearcherOregon Health & Science UniversityActive in the last 2 years

Aaron J. Grossberg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4690-4948; OpenAlex author ID A5045078700; NIH RePORTER profile ID 9605952. Sources: ClinicalTrials.gov.

Their work

Papers
23 (first author 1, last author 6)
Trials
1 (principal investigator on 1)
Grants
2
Labs led
1
Collaborators
93
Papers, trials and grants by year

2020: 1 paper, 1 trial · 2021: 2 papers · 2022: 3 papers · 2023: 5 papers · 2024: 3 papers, 1 grant · 2025: 4 papers · 2026: 5 papers, 1 grant

Papers 23

  1. Impaired Adipose Anabolism in Pancreatic Cancer Cachexia Is Reversed by HuR Inhibition. Last author DOI 10.1002/jcsm.70253↗
  2. Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for clinical trial design. Co-author DOI 10.1016/j.canlet.2026.218864↗
  3. Interleukin 6 Drives Durable T Cell-Mediated Immunity to Pancreatic Cancer. Last author DOI 10.1016/j.jcmgh.2026.101768↗
  4. Pancreatic cancer cachexia promotes cardiac dysfunction through altered adrenergic signalling in the heart. Last author DOI 10.1113/jp290616↗
  5. The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1136/jitc-2025-sitc2025.1250↗
  6. Perioperative Radiation for Patients with Resectable Pancreatic Cancer: an Updated Review After the Initial RTOG 0848 Results. First author DOI 10.1007/s12029-025-01185-0↗
  7. Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients. Co-author DOI 10.1038/s41467-025-62685-y↗
  8. Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.02.07.632847↗
  9. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  10. Hepatic signal transducer and activator of transcription-3 signalling drives early-stage pancreatic cancer cachexia via suppressed ketogenesis. Last author DOI 10.1002/jcsm.13466↗
  11. GDF15 and LCN2 for early detection and prognosis of pancreatic cancer. Co-author DOI 10.1016/j.tranon.2024.102129↗
  12. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  13. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. Co-author DOI 10.1001/jamaoncol.2022.6135↗
  14. Socioeconomic and Geographic Disparities in the Referral and Treatment of Pancreatic Cancer at High-Volume Centers. Co-author DOI 10.1001/jamasurg.2022.6709↗
  15. Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic… Co-author DOI 10.1002/cam4.5971↗
  16. Neoadjuvant therapy does not impact the biliary microbiome in patients with pancreatic cancer. Co-author DOI 10.1002/jso.27281↗
  17. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  18. Validation of automated body composition analysis using diagnostic computed tomography imaging in patients with pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2022.03.025↗
  19. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  20. Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasin… Last author DOI 10.3390/cancers14030609↗
  21. Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia. Co-author DOI 10.1038/s41467-021-22361-3↗
  22. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  23. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Co-author DOI 10.3322/caac.21626↗

Trials 1

  1. Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer Principal investigator NCT04400903↗

Grants 2

  1. Metabolic vulnerability due to dysregulated lipid metabolism in PDAC cachexia R37CA280692↗
  2. Hepatic metabolic reprogramming drives pancreatic cancer cachexia K08CA245188↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rosalie C. Sears · 6 shared papers, 2021–2026 · strength 1.12
  2. Paige C. Arneson‐Wissink · 4 shared papers, 2024–2026 · strength 1.00
  3. Jonathan Robert Brody · 4 shared papers, 2025–2026 · strength 0.97
  4. Parham Diba · 4 shared papers, 2024–2026 · strength 0.96
  5. Robert L Eil · 4 shared papers, 2024–2026 · strength 0.89
  6. Charles D. Lopez · 5 shared papers, 2022–2026 · strength 0.88
  7. Daniel L. Marks · 5 shared papers, 2020–2026 · strength 0.83
  8. Katherine R. Pelz · 4 shared papers, 2021–2026 · strength 0.83
  9. Brett C. Sheppard · 5 shared papers, 2022–2023 · strength 0.79
  10. Grace A. McCarthy · 3 shared papers, 2025–2026 · strength 0.70
  11. Jennifer M. Finan · 3 shared papers, 2025–2026 · strength 0.69
  12. Thomas Lee Sutton · 4 shared papers, 2022–2023 · strength 0.64
  13. Skye C. Mayo · 4 shared papers, 2022–2023 · strength 0.62
  14. Xinxia Zhu · 3 shared papers, 2021–2026 · strength 0.55
  15. Cymon N. Kersch · 1 shared paper, 2025 · strength 0.54
  16. Adel Kardosh · 3 shared papers, 2022–2026 · strength 0.53
  17. Katelyn T. Byrne · 2 shared papers, 2026 · strength 0.51
  18. Ariana L. Sattler · 2 shared papers, 2024–2026 · strength 0.44
  19. Diane M. Simeone · 4 shared papers, 2020–2024 · strength 0.43
  20. Lisa M. Coussens · 2 shared papers, 2025–2026 · strength 0.43
  21. Yifei Guo · 2 shared papers, 2025–2026 · strength 0.43
  22. Kevin Hawthorne · 2 shared papers, 2025–2026 · strength 0.43
  23. Katie E. Blise · 2 shared papers, 2025–2026 · strength 0.43
  24. Zheng Xia · 2 shared papers, 2025–2026 · strength 0.43
  25. Canping Chen · 2 shared papers, 2025–2026 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.